ストックスクリーナーアプリを入手
0.8006
23.02%
-0.2394
アフターアワーズ：
.78
-0.0206
-2.57%
前日終値:
$1.04
開ける：
$1.18
24時間の取引高:
18.73M
Relative Volume:
17.31
時価総額：
$14.79M
収益：
-
当期純損益:
$-39.14M
株価収益率:
-0.1341
EPS:
-5.97
ネットキャッシュフロー:
$-28.20M
1週間 パフォーマンス:
-23.02%
1か月 パフォーマンス:
-29.77%
6か月 パフォーマンス:
-37.94%
1年 パフォーマンス:
-74.42%
1日の値動き範囲:
$0.63
$1.18
1週間の範囲:
$0.63
$1.18
52週間の値動き範囲:
$0.63
$5.95
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
CTXR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.8006 | 19.21M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Dow Gains Over 100 Points; US Jobless Claims Decline - Benzinga
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED) - Benzinga
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Citius Pharmaceuticals Inc. Full Year Loss Decreases - Nasdaq
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals, Inc. reports fiscal year 2025 financial results and provides business update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. - Investing.com
CTXR: LYMPHIR's U.S. launch marks a pivotal year, with strong capital raises and ongoing pipeline progress - TradingView — Track All Markets
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - Fidelity
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
How interest rate cuts could boost Citius Pharmaceuticals Inc. stockShort Setup & Stock Portfolio Risk Management - Улправда
Why Citius Pharmaceuticals Inc. stock remains resilientPortfolio Performance Report & Technical Pattern Based Buy Signals - Улправда
Is Citius Pharmaceuticals Inc. (47N0) stock a safe buy pre earningsExit Point & Daily Oversold Bounce Ideas - Bölüm Sonu Canavarı
Can Citius Pharmaceuticals Inc. stock resist market sell offsWeekly Stock Summary & Proven Capital Preservation Tips - Улправда
Sell Signal: How Citius Pharmaceuticals Inc. stock trades before earnings2025 Biggest Moves & Daily Growth Stock Investment Tips - Улправда
What analyst consensus says on Citius Pharmaceuticals Inc. stockJuly 2025 Recap & Low Risk High Win Rate Picks - DonanımHaber
Layoff Watch: Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsWeekly Profit Summary & Community Consensus Trade Signals - Улправда
Analyst Calls: Will Citius Pharmaceuticals Inc. stock maintain dividend yieldInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
Will Citius Pharmaceuticals Inc. (47N0) stock outperform energy sector in 2025July 2025 Big Picture & Free Weekly Chart Analysis and Trade Guides - DonanımHaber
Will Citius Pharmaceuticals Inc. stock maintain dividend yieldTrade Ideas & Free Real-Time Volume Trigger Notifications - DonanımHaber
Will Citius Pharmaceuticals Inc. stock see insider buyingJuly 2025 Chart Watch & Real-Time Buy Signal Alerts - DonanımHaber
Citius Pharmaceuticals Earnings Notes - Trefis
Is Citius Pharmaceuticals Inc. stock positioned for digital transformationOil Prices & Real-Time Volume Surge Alerts - ulpravda.ru
Why Citius Pharmaceuticals Inc. stock remains a top recommendationJuly 2025 Reactions & Real-Time Chart Breakout Alerts - Улправда
Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow JonesJuly 2025 PreEarnings & Weekly Return Optimization Plans - Улправда
Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - Улправда
Quarterly Earnings: How interest rate cuts could boost Citius Pharmaceuticals Inc. stockAnalyst Upgrade & Accurate Entry/Exit Alerts - Улправда
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology (Nasdaq: CTOR) raises $18M at-the-market to fund LYMPHIR - Stock Titan
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Finviz
Aug Selloffs: Is Citius Pharmaceuticals Inc stock positioned for digital transformationPortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Citius Pharmaceuticals Inc. (47N0) stock good for wealth creationJuly 2025 Momentum & Safe Investment Capital Preservation Plans - Newser
How Citius Pharmaceuticals Inc. (47N0) stock reacts to fiscal policiesJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
CTXR: Analyst Jason Kolbert Maintains 'Buy' Rating with $6 Price Target | CTXR Stock News - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - Finviz
How supply shortages influence Citius Pharmaceuticals Inc. (47N0) stockWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
How Citius Pharmaceuticals Inc. (47N0) stock responds to bond market2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.21%
大文字化:
|
ボリューム (24 時間):